NASDAQ:IONS Ionis Pharmaceuticals (IONS) Stock Forecast, Price & News $45.36 -0.90 (-1.95%) (As of 09/29/2023 ET) Add Compare Share Share Today's Range$45.22▼$47.0050-Day Range$38.50▼$47.1352-Week Range$32.69▼$47.74Volume1.34 million shsAverage Volume1.05 million shsMarket Capitalization$6.49 billionP/E RatioN/ADividend YieldN/APrice Target$49.45 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Ionis Pharmaceuticals MarketRank™ ForecastAnalyst RatingModerate Buy2.60 Rating ScoreUpside/Downside9.0% Upside$49.45 Price TargetShort InterestBearish6.70% of Float Sold ShortDividend StrengthN/ASustainability-3.58Upright™ Environmental ScoreNews Sentiment0.61Based on 36 Articles This WeekInsider TradingSelling Shares$1.62 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($3.35) to ($3.56) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.19 out of 5 starsMedical Sector950th out of 972 stocksPharmaceutical Preparations Industry444th out of 453 stocks 1.3 Analyst's Opinion Consensus RatingIonis Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 5 buy ratings, 3 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $49.45, Ionis Pharmaceuticals has a forecasted upside of 9.0% from its current price of $45.36.Amount of Analyst CoverageIonis Pharmaceuticals has only been the subject of 4 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted6.70% of the float of Ionis Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverIonis Pharmaceuticals has a short interest ratio ("days to cover") of 10.1, which indicates bearish sentiment.Change versus previous monthShort interest in Ionis Pharmaceuticals has recently increased by 0.97%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldIonis Pharmaceuticals does not currently pay a dividend.Dividend GrowthIonis Pharmaceuticals does not have a long track record of dividend growth. Previous Next 3.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreIonis Pharmaceuticals has received a 27.23% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Neuromuscular disorders medication" product. See details.Environmental SustainabilityThe Environmental Impact score for Ionis Pharmaceuticals is -3.58. Previous Next 2.6 News and Social Media Coverage News SentimentIonis Pharmaceuticals has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 36 news articles for Ionis Pharmaceuticals this week, compared to 4 articles on an average week.Search Interest22 people have searched for IONS on MarketBeat in the last 30 days. This is an increase of 175% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Ionis Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ionis Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,622,932.00 in company stock.Percentage Held by InsidersOnly 2.65% of the stock of Ionis Pharmaceuticals is held by insiders.Percentage Held by Institutions93.86% of the stock of Ionis Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Ionis Pharmaceuticals are expected to decrease in the coming year, from ($3.35) to ($3.56) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ionis Pharmaceuticals is -20.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ionis Pharmaceuticals is -20.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIonis Pharmaceuticals has a P/B Ratio of 11.26. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Ionis Pharmaceuticals (NASDAQ:IONS) StockIonis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops Cimdelirsen to inhibit the production of growth hormone receptor; IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. Ionis Pharmaceuticals, Inc. was incorporated in 1989 and is based in Carlsbad, California.Read More IONS Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IONS Stock News HeadlinesOctober 1, 2023 | americanbankingnews.comC Frank Bennett Sells 4,460 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) StockOctober 1, 2023 | americanbankingnews.comB Lynne Parshall Sells 10,000 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) StockOctober 1, 2023 | Porter and Company (Ad)The Elites Are Waging War on Elon Musk — Here's Why…Elon has helped unleash an opportunity that could create trillions in wealth for everyday Americans. So why does the deep state hate him for it?September 30, 2023 | msn.comRaymond James Initiates Coverage of Ionis Pharmaceuticals (IONS) with Strong Buy RecommendationSeptember 30, 2023 | finance.yahoo.comInsider Sell: EVP, Chief Scientific Officer C Bennett Sells 4,460 Shares of Ionis ...September 30, 2023 | americanbankingnews.comIonis Pharmaceuticals (NASDAQ:IONS) Stock Rating Reaffirmed by Needham & Company LLCSeptember 30, 2023 | americanbankingnews.comLeerink Partnrs Analysts Lift Earnings Estimates for Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)September 30, 2023 | americanbankingnews.comIonis Pharmaceuticals (NASDAQ:IONS) Coverage Initiated at Raymond JamesOctober 1, 2023 | Chaikin Analytics (Ad)This Stock Could Go Up 66% or More.Marc Chaikin built the system that isolated NVDA before it became the best-performing stock of 2023. Click here to get his latest buy. More here.September 29, 2023 | finance.yahoo.comInsider Sell: Director B Parshall Sells 10,000 Shares of Ionis Pharmaceuticals IncSeptember 28, 2023 | finance.yahoo.comIonis (IONS) Inks New Deal With Roche to Develop Novel RNA DrugsSeptember 28, 2023 | finance.yahoo.comEplontersen Phase 3 results published in JAMA show consistent and sustained benefitSeptember 28, 2023 | americanbankingnews.comMorgan Stanley Increases Ionis Pharmaceuticals (NASDAQ:IONS) Price Target to $45.00September 27, 2023 | msn.comIonis' metabolic disorder drug lowers high levels of a type of fat in studySeptember 27, 2023 | finance.yahoo.comStrength Seen in Ionis Pharmaceuticals (IONS): Can Its 8.5% Jump Turn into More Strength?September 27, 2023 | finance.yahoo.comIonis (IONS) Meets Rare Disease Drug Study Goal, Stock Up 8.5%September 27, 2023 | finance.yahoo.comIonis enters agreement with Roche for two novel RNA-targeted programs for Alzheimer's disease and Huntington's diseaseSeptember 26, 2023 | msn.comIonis Pharmaceuticals' Rare Metabolic Disorder Candidate Poised To Become New Standard Treatment, Study Shows Encouraging ActionSeptember 26, 2023 | msn.comIonis late-stage rare disease data fails to impress BernsteinSeptember 26, 2023 | finance.yahoo.comIonis Climbs On Late-Stage Trial Results For Body Fat DisorderSeptember 26, 2023 | reuters.comIonis Pharma's genetic disorder drug succeeds in late-stage studySeptember 26, 2023 | markets.businessinsider.comIonis Reports Positive Results From Phase 3 Study Of Olezarsen In Familial Chylomicronemia SyndromeSeptember 26, 2023 | reuters.comIonis Pharma's genetic disorder drug meets main goal in late-stage studySeptember 26, 2023 | finance.yahoo.comIonis announces positive olezarsen topline results from Phase 3 study in people with familial chylomicronemia syndromeSeptember 26, 2023 | finance.yahoo.comUPDATE 2-Ionis' metabolic disorder drug lowers high levels of a type of fat in studySeptember 21, 2023 | americanbankingnews.comIonis Pharmaceuticals, Inc. (NASDAQ:IONS) Given Average Recommendation of "Hold" by AnalystsSeptember 21, 2023 | americanbankingnews.comLeerink Partnrs Comments on Ionis Pharmaceuticals, Inc.'s Q3 2023 Earnings (NASDAQ:IONS)See More Headlines Receive IONS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ionis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address IONS Company Calendar Last Earnings8/09/2023Today10/01/2023Next Earnings (Estimated)11/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:IONS CUSIP46433010 CIK874015 Webwww.ionispharma.com Phone(760) 931-9200Fax760-603-2700Employees796Year FoundedN/APrice Target and Rating Average Stock Price Forecast$49.45 High Stock Price Forecast$67.00 Low Stock Price Forecast$27.00 Forecasted Upside/Downside+9.0%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($2.17) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-269,720,000.00 Net Margins-48.81% Pretax Margin-44.60% Return on Equity-59.17% Return on Assets-11.40% Debt Debt-to-Equity Ratio3.07 Current Ratio9.09 Quick Ratio9.00 Sales & Book Value Annual Sales$587 million Price / Sales11.06 Cash FlowN/A Price / Cash FlowN/A Book Value$4.03 per share Price / Book11.26Miscellaneous Outstanding Shares143,100,000Free Float139,308,000Market Cap$6.49 billion OptionableOptionable Beta0.51 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesDr. Brett P. Monia Ph.D. (Age 62)Founder, CEO & Director Comp: $1.71MMs. Elizabeth L. Hougen M.A. (Age 61)M.B.A., M.S., Exec. VP of Fin. & CFO Comp: $1.02MMs. Onaiza Cadoret-Manier M.A. (Age 58)M.B.A., M.S., Exec. VP, Chief Global Product Strategy & Operations Officer Comp: $930.82kMs. B. Lynne Parshall Esq. (Age 69)J.D., Sr. Strategic Advisor & Director Comp: $334.64kDr. Richard S. Geary Ph.D. (Age 65)Exec. VP & Chief Devel. Officer Comp: $946.26kMr. Joseph T. Baroldi M.A. (Age 44)M.B.A., M.S., Exec. VP & Chief Bus. Officer Comp: $815.87kMr. Darren GonzalesChief Accounting Officer & Sr. VPDr. C. Frank Bennett BSc (Age 66)Ph.D., Exec. VP & Chief Scientific Officer Mr. D. Wade Walke Ph.D.Sr. VP of Investor RelationsMr. Patrick R. O'Neil Esq. (Age 49)Exec. VP, Chief Legal Officer, Gen. Counsel & Corp. Sec. More ExecutivesKey CompetitorsAlkermesNASDAQ:ALKSImmunoGenNASDAQ:IMGNAmicus TherapeuticsNASDAQ:FOLDMadrigal PharmaceuticalsNASDAQ:MDGLUnited TherapeuticsNASDAQ:UTHRView All CompetitorsInsiders & InstitutionsC Frank BennettSold 4,460 sharesTotal: $207,390.00 ($46.50/share)B Lynne ParshallSold 10,000 sharesTotal: $451,300.00 ($45.13/share)Virginia Retirement Systems ET ALBought 34,600 shares on 8/22/2023Ownership: 0.024%Comerica BankBought 538 shares on 8/22/2023Ownership: 0.000%California State Teachers Retirement SystemSold 4,182 shares on 8/21/2023Ownership: 0.112%View All Insider TransactionsView All Institutional Transactions IONS Stock - Frequently Asked Questions Should I buy or sell Ionis Pharmaceuticals stock right now? 10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ionis Pharmaceuticals in the last year. There are currently 1 sell rating, 3 hold ratings, 5 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" IONS shares. View IONS analyst ratings or view top-rated stocks. What is Ionis Pharmaceuticals' stock price forecast for 2023? 10 Wall Street analysts have issued 12 month target prices for Ionis Pharmaceuticals' stock. Their IONS share price forecasts range from $27.00 to $67.00. On average, they expect the company's share price to reach $49.45 in the next year. This suggests a possible upside of 9.0% from the stock's current price. View analysts price targets for IONS or view top-rated stocks among Wall Street analysts. How have IONS shares performed in 2023? Ionis Pharmaceuticals' stock was trading at $37.77 at the beginning of the year. Since then, IONS stock has increased by 20.1% and is now trading at $45.36. View the best growth stocks for 2023 here. When is Ionis Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023. View our IONS earnings forecast. How were Ionis Pharmaceuticals' earnings last quarter? Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) posted its quarterly earnings data on Wednesday, August, 9th. The company reported $0.60 EPS for the quarter, beating the consensus estimate of ($0.94) by $1.54. The firm had revenue of $188 million for the quarter, compared to analysts' expectations of $136.84 million. Ionis Pharmaceuticals had a negative trailing twelve-month return on equity of 59.17% and a negative net margin of 48.81%. What ETFs hold Ionis Pharmaceuticals' stock? ETFs with the largest weight of Ionis Pharmaceuticals (NASDAQ:IONS) stock in their portfolio include ARK Genomic Revolution ETF (ARKG), Morningstar US Small Growth (MSGR), First Trust NYSE Arca Biotechnology Index Fund (FBT), Horizon Kinetics Medical ETF (MEDX), Franklin Genomic Advancements ETF (HELX), Virtus LifeSci Biotech Products ETF (BBP), Principal Healthcare Innovators ETF (BTEC) and VanEck Morningstar SMID Moat ETF (SMOT). What guidance has Ionis Pharmaceuticals issued on next quarter's earnings? Ionis Pharmaceuticals updated its FY 2023 earnings guidance on Thursday, August, 10th. The company provided EPS guidance of for the period. The company issued revenue guidance of $575.00M-, compared to the consensus revenue estimate of $586.28 million. What other stocks do shareholders of Ionis Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ionis Pharmaceuticals investors own include CA (CA), Micron Technology (MU), NVIDIA (NVDA), Gilead Sciences (GILD), Alibaba Group (BABA), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), BlackRock (BLK), Skyworks Solutions (SWKS) and Advanced Micro Devices (AMD). What is Ionis Pharmaceuticals' stock symbol? Ionis Pharmaceuticals trades on the NASDAQ under the ticker symbol "IONS." How do I buy shares of Ionis Pharmaceuticals? Shares of IONS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Ionis Pharmaceuticals' stock price today? One share of IONS stock can currently be purchased for approximately $45.36. How much money does Ionis Pharmaceuticals make? Ionis Pharmaceuticals (NASDAQ:IONS) has a market capitalization of $6.49 billion and generates $587 million in revenue each year. The company earns $-269,720,000.00 in net income (profit) each year or ($2.17) on an earnings per share basis. How many employees does Ionis Pharmaceuticals have? The company employs 796 workers across the globe. How can I contact Ionis Pharmaceuticals? Ionis Pharmaceuticals' mailing address is 2855 GAZELLE COURT, CARLSBAD CA, 92010. The official website for the company is www.ionispharma.com. The company can be reached via phone at (760) 931-9200, via email at wwalke@ionisph.com, or via fax at 760-603-2700. This page (NASDAQ:IONS) was last updated on 10/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ionis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.